# Signals Article: Putative Target O00401 for Shigella Vaccine
Background
*Shigella* species are a leading cause of bacterial dysentery, particularly affecting children in low-resource settings. Developing an effective vaccine against *Shigella* could significantly reduce the incidence of this debilitating disease. Despite ongoing research efforts, no *Shigella* vaccine has yet reached advanced clinical trials, highlighting the need for novel targets.
Data-mining rationale
In a recent reanalysis effort, UniProt entry O00401 was identified as a putative target for a *Shigella* vaccine. This candidate emerged from cross-referencing UniProt's reviewed human entries with expression-profiling studies in the NCBI GEO database. Although O00401 is present in these studies, it has not been associated with any registered Phase 1 or higher clinical programs, suggesting its potential as an unexplored target.
Why prior analyses may have missed this
Many of the GEO datasets containing O00401 predate modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier analyses may have led to the underestimation of O00401's potential as a vaccine target. Additionally, the lack of integration with pathway and tissue-specific databases may have obscured its relevance.
Reasoning for further validation
To fully assess the potential of O00401 as a vaccine target, several steps are recommended. Re-analyzing the matched GEO datasets using limma with Benjamini-Hochberg FDR correction will provide a more accurate picture of differential expression. Validation of top differentially-expressed genes by qPCR in an independent cohort is essential to confirm findings. Checking tissue specificity in GTEx and the Human Protein Atlas will help determine the target's relevance in the context of *Shigella* infection. Running pathway analyses using STRING or OmniPath will provide insights into the biological context of O00401. If validated, assessing the druggability of O00401 via DGIdb and ChEMBL will be crucial for potential therapeutic development.